Moderator:
Ranjana H. Advani, MD 
Stanford Cancer Institute

Panelists:
Mark W. Clemens, II, MD
The University of Texas MD Anderson Cancer Center

Youn H. Kim, MD
Stanford Cancer Institute

Jane N. Winter, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Andrew D. Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN Continuing Education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

The faculty listed below discloses no relevant financial relationships:
Mark W. Clemens, II, MD

The faculty listed below discloses the following relevant financial relationships:
Ranjana H. Advani, MD
Agensys, Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Consulting Fees, Honoraria
Bayer HealthCare: Consulting Fees, Honoraria
Bristol-Myers Squibb Company: Consulting Fees, Honoraria; Grant/Research Support
Celgene Corporation: Grant/Research Support
Cell Medica: Scientific Advisor
Forty Seven, Inc.: Grant/Research Support
Genentech, Inc.: Consulting Fees, Honoraria; Grant/Research Support
Gilead Sciences, Inc.: Consulting Fees, Honoraria
Infinity Pharmaceuticals, Inc.: Grant/Research Support
Janssen Pharmaceutica Products, LP: Grant/Research Support
Juno Therapeutics: Consulting Fees, Honoraria
Kura Oncology, Inc.: Grant/Research Support
Merck & Co., Inc.: Grant/Research Support
Millennium Pharmaceuticals, Inc.: Grant/Research Support
NanoString® Technologies, Inc.: Consulting Fees, Honoraria
Pharmacyclics: Consulting Fees, Honoraria; Grant/Research Support
Regeneron Pharmaceuticals, Inc.: Grant/Research Support
Roche Laboratories, Inc.: Consulting Fees, Honoraria; Grant/Research Support
Seattle Genetics, Inc.: Consulting Fees, Honoraria; Grant/Research Support
Sutro Biopharma, Inc.: Consulting Fees, Honoraria
Teva Pharmaceutical Industries Ltd.: Grant/Research Support

Youn H. Kim, MD
Actelion Pharmaceuticals Ltd: Consulting Fees, Honoraria; Scientific Advisor
Eisai Inc.: Scientific Advisor
Forty Seven, Inc.: Scientific Advisor
Kyowa Hakko Kirin Co., Ltd.: Scientific Advisor
Medivir: Consulting Fees, Honoraria; Scientific Advisor
Millennium Pharmaceuticals, Inc./Takeda Pharmaceutical Company Limited: Scientific Advisor
miRagen Therapeutics, Inc.: Scientific Advisor
Portola Pharmaceuticals, Inc.: Consulting Fees, Honoraria
Seattle Genetics, Inc.: Scientific Advisor

Jane N. Winter, MD
*ARIAD Pharmaceuticals, Inc.: Consulting Fees, Honoraria
*Astellas Pharma US, Inc.: Grant/Research Support
*Bristol-Myers Squibb Company: Consulting Fees, Honoraria
*Celgene Corporation: Consulting Fees, Honoraria; Grant/Research Support
*CVS/Caremark: Consulting Fees, Honoraria
*Daiichi- Sankyo Co.: Grant/Research Support
*Erytech: Grant/Research Support
Gilead Sciences, Inc.: Consulting Fees, Honoraria
GlaxoSmithKline: Grant/Research Support
Janssen Pharmaceutica Products, LP: Grant/Research Support 
Merck & Co., Inc.: Grant/Research Support
*Novartis Pharmaceuticals Corporation: Consulting Fees, Honoraria *Pfizer Inc.: Scientific Advisor
Pharmacyclics: Consulting Fees, Honoraria
Seattle Genetics, Inc.: Grant/Research Support

Andrew D. Zelenetz, MD, PhD
Adaptive Biotechnologies: Consulting Fees, Honoraria
Amgen Inc.: Consulting Fees, Honoraria
BeiGene: Grant/Research Support
Bristol-Myers Squibb Company: Grant/Research Support
Celgene Corporation: Consulting Fees, Honoraria
Genentech, Inc.: Consulting Fees, Honoraria
Gilead Sciences, Inc.: Consulting Fees, Honoraria; Grant/Research Support
Janssen Pharmaceutica Products, LP: Consulting Fees, Honoraria; Grant/Research Support
MEI Pharma Inc.: Grant/Research Support
NanoString® Technologies, Inc.: Consulting Fees, Honoraria
Portola Pharmaceuticals, Inc.: Consulting Fees, Honoraria
Roche Laboratories, Inc.: Consulting Fees, Honoraria; Grant/Research Support
Takeda Pharmaceuticals North America, Inc.: Consulting Fees, Honoraria

* signifies the relationship relates to the individual's spouse/partner

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Kimberly Bayer; Robert W. Carlson, MD; Melissa Esplen; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Donald Harting, MA, ELS, CHCP; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Kimbro, MBA, CPA; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Melinda Somasekhar, PhD (employed by NCCN until October 30, 2017); Gary J. Weyhmuller, MBA, SPHR

The NCCN Clinical Information staff listed below, who has reviewed content, discloses no relevant financial relationships:
Mary Dwyer, MS; Hema Sundar, PhD

Definitions
The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use.  Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.